AGMB-129

DRUG4 trials

Sponsors

Agomab Spain S.L.U., Agomab Spain S.L.

Conditions

Fibrostenotic Crohn's DiseaseHealthy Volunteers

Phase 1

Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

CompletedNCT05937386

Agomab Spain S.L.Healthy Volunteers

Start: 2023-08-09End: 2023-09-06Updated: 2024-06-18

Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

CompletedNCT06397508

Agomab Spain S.L.Healthy Volunteers

Start: 2024-04-02End: 2024-05-13Updated: 2024-05-16

A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants

CompletedNCT07118878

Agomab Spain S.L.U.Fibrostenotic Crohn's Disease

Start: 2025-08-06End: 2025-09-15Updated: 2025-11-21

Phase 2

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

CompletedNCT05843578

Agomab Spain S.L.U.Fibrostenotic Crohn's Disease

Start: 2023-08-01End: 2026-06-20Updated: 2026-07-09

Related Papers

P0334 AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects

Journal of Crohn s and Colitis2025-01-012 citations